Get startedLog in
    Picture of Kdventures AB logo

    KDV B — Kdventures AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    FinancialsSpeculativeMicro CapSucker Stock
    All News

    Brief: Karolinska Development’s Portfolio Company Umecrine Cognition Presents Positive Results

    Picture of Kdventures AB logoKdventures AB
    28/09/2022 08:20
    Sept 28 (Reuters) - Karolinska Development AB  KDEV.ST :
    * PORTFOLIO COMPANY UMECRINE COGNITION PRESENTS POSITIVE
RESULTS
FROM A PRECLINICAL STUDY OF GOLEXANOLONE
    * PORTFOLIO COMPANY UMECRINE COGNITION HAS PRESENTED NEW
PRECLINICAL RESULTS THAT PROVIDE FURTHER SUPPORT FOR COMPANY'S
MOST ADVANCED DRUG CANDIDATE GOLEXANOLONE IN TREATMENT OF RARE
AUTOIMMUNE DISEASE PRIMARY BILIARY CHOLANGITIS (PBC)

Source text for Eikon:  ID:nGNE64rk7g 
Further company coverage:  KDEV.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Kdventures AB

    See all news